<DOC>
	<DOCNO>NCT00454207</DOCNO>
	<brief_summary>To assess safety sildenafil 20 mg TID orally give Japanese pulmonary arterial hypertension patient ( Part 1 2 ) To assess efficacy 12 week treatment sildenafil 20 mg TID orally give Japanese pulmonary arterial hypertension patient ( Part 1 )</brief_summary>
	<brief_title>Open Label Study Sildenafil Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Subjects age 16 , classify pulmonary arterial hypertension Subjects meet follow condition right heart catheterization screen baseline : mean pulmonary arterial pressure ≥ 25mmHg pulmonary capillary wedge pressure ≤ 15mmHg rest Subjects whose baseline 6Minute Walk test distance &gt; 100 &lt; 450 Significant Hepatic and/or renal disorder Subjects know hereditary degenerative retinal disorder ( retinitis pigmentosa ) history nonarteritic ischemic optic neuropathy ( NAION ) Subjects currently receive nitrate nitric oxide donor form , ritonavir , ketoconazole itraconazole</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Pulmonary Arterial Hypertension , PAH</keyword>
</DOC>